Sinovac Biotech has received third purchase order for its H1N1 vaccine, PANFLU.1, from China’s Ministry of Industry and Information Technology for the national stockpiling plan.
Under the purchase order, Sinovac is required to produce an additional 5.19 million doses of PANFLU.1 (15ug/0.5ml) for the Chinese central government. Moreover, Sinovac is required to complete delivery of 2.89 million doses to the appointed provincial and municipal governments by the end of this year and supply the remaining 2.3 million doses for the central government stockpiling.
Reportedly, this order is in addition to an initial order for 3.3 million doses and second order for three million doses from the Ministry of Industry and Information Technology of China for a total of 11.49 million doses.
The company has also competed and won the bidding process to supply its seasonal flu vaccine, Anflu, to the Shanghai government. The purchase plan from the Shanghai government reflects an expansion of government purchase programs for the seasonal flu vaccine.
Weidong Yin, chairman, president and CEO of Sinovac, said: “We are very proud to be supplying our H1N1 vaccine to the Chinese government and are confident that we can complete the national H1N1 vaccine stockpiling task in a timely manner. We continue to work towards our goal of providing citizens of China with affordable, international-quality vaccines. The agreement with the Shanghai Municipal Center for Disease Control and Prevention brings us closer to our goal as it opened up another important public market in China.”